Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FG62E
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,892.90 by the Defense Logistics Agency on September 16, 2025, for the supply of Nucala 100 mg/ml auto-injectors. The delivery order, which carries no set-aside designation, is scheduled for ultimate completion on September 17, 2025, with performance at the contractor's Park Ridge location. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to issue delivery orders for comprehensive pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
As a established federal pharmaceutical supplier since 2001, DMS Pharmaceutical Group has demonstrated consistent capability in delivering specialized pharmaceutical products to military and federal healthcare systems. The Nucala auto-injector delivery, used primarily for treating severe eosinophilic asthma and other eosinophil-related conditions, represents another instance of the contractor's role as a critical component of the federal pharmaceutical supply chain. The firm fixed-price structure and brief completion timeline reflect the standard operational parameters of the DLA's delivery order process, ensuring efficient procurement of essential medical supplies for military health facilities.
Quick answers
Who was awarded contract SPE2DB25FG62E?
SPE2DB25FG62E was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 16, 2025.
How much is contract SPE2DB25FG62E worth?
The government has obligated $1,893 on SPE2DB25FG62E.
Is contract SPE2DB25FG62E an order under another contract?
Yes. SPE2DB25FG62E is a delivery order under SPE2DB20D9157, an indefinite delivery contract.
Was contract SPE2DB25FG62E competed?
The extent of competition for SPE2DB25FG62E was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award